| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2004 | US6693097 Antiinflammatory agents; antidiabetic agents; skin disorders; rheumatic diseases |
| 02/17/2004 | US6693096 Treatment of inflammation-associated disorders using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
| 02/17/2004 | US6693094 Supporting mitochondrial metabolism with a unit dosage form of choline, ascorbate, l-carnitine, magnesium, taurine, folic acid and metformin |
| 02/17/2004 | US6693090 19-norsteroids substituted in position 11β, preparation process and intermediates, application as medicines and pharmaceutical compositions containing them |
| 02/17/2004 | US6693088 Inhibiting in vivo leukocyte adhesion |
| 02/17/2004 | US6693085 Has an activity against mrsa (methicillin-resistant staphylococcus aureus). |
| 02/17/2004 | US6693079 Insulin-like growth factor agonist molecules |
| 02/17/2004 | US6693078 Insulin-like growth factor agonist molecules |
| 02/17/2004 | US6693073 Pulmonary delivery of active agents |
| 02/17/2004 | US6692943 Persephin and related growth factors |
| 02/17/2004 | US6692936 Novel polypeptide belonging to the class of proteins known as g-protein coupled receptors |
| 02/17/2004 | US6692911 Cell delivery compositions |
| 02/17/2004 | US6692777 Pharmaceutical composition for the treatment of diabetes mellitus |
| 02/17/2004 | US6692772 Administered between 15 and 90 minutes prior to exposure of the subject to thrombogenic stimuli |
| 02/17/2004 | US6692764 Treatment and prevention of diseases involving bone resorption, especially osteoporosis, paget's disease, malignant hypercalcemia, and metastatic bone disease; binder-free tablets |
| 02/17/2004 | US6692763 Equivalent to a serum estadiol level not exceeding of between about 5 pg/ml and about 15 pg/ml, for treatment of physical conditions associated with menopause: hot flashes; bone loss; headache; nausea etc. |
| 02/17/2004 | US6692762 Generating linoleic acid derivatives; obtain chemical intermediates, incubate with lipase, recover fatty acid conjugated to linoleic acid |
| 02/17/2004 | US6692754 Cosmetic composition |
| 02/17/2004 | US6692742 Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| 02/17/2004 | US6692741 Treatment of acute lung injury and fibrosis with antagonists of β6-specific antibodies |
| 02/17/2004 | US6692734 N,O-amidomalonate platinum complexes |
| 02/17/2004 | US6692732 Administering cationic polymers to mammals to prevent poisons or antigens from microorganisms such as bacteria, viruses, fungi or parasites; deactivation |
| 02/17/2004 | US6691770 Cooling apparatus |
| 02/17/2004 | CA2408585C Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals |
| 02/17/2004 | CA2302965C Processes and intermediates for preparing anti-cancer compounds |
| 02/17/2004 | CA2293823C 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives |
| 02/17/2004 | CA2290969C Delayed-release dosage forms of sertraline |
| 02/17/2004 | CA2290918C Heteroaromatic bicyclic derivatives useful as anticancer agents |
| 02/17/2004 | CA2287482C Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors |
| 02/17/2004 | CA2280279C Indole, indazole and benzimidazole derivatives as antithrombotic agents |
| 02/17/2004 | CA2268908C Pharmaceutical and cosmetic antiacne formulations containing plant extracts (krameria triandra or mesua ferrea) |
| 02/17/2004 | CA2252401C Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
| 02/17/2004 | CA2249299C Combination of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum |
| 02/17/2004 | CA2214319C Novel taxoids, preparation thereof and pharmaceutical compositions containing same |
| 02/17/2004 | CA2124680C Piperazine derivatives as 5-ht1a antagonists |
| 02/17/2004 | CA2079161C N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines |
| 02/17/2004 | CA2075288C Anthracycline-conjugates |
| 02/17/2004 | CA2074348C Stable compositions for parenteral administration and their use |
| 02/17/2004 | CA2051501C 1-phenyl-3-phenyl-2-propyne-1-ones as calcium uptake inhibitors |
| 02/14/2004 | CA2823474A1 Botanical drug substances comprising various proportions of thc and cbd |
| 02/14/2004 | CA2455129A1 Improvements in the extraction of pharmaceutically active components from plant materials |
| 02/13/2004 | CA2395819A1 Dual-spike release formulation for oral drug delivery |
| 02/12/2004 | WO2004013629A2 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases |
| 02/12/2004 | WO2004013310A2 Methods of down regulating target gene expression in vivo by introduction of interfering rna |
| 02/12/2004 | WO2004013309A2 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE |
| 02/12/2004 | WO2004013300A2 Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections |
| 02/12/2004 | WO2004013298A2 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections |
| 02/12/2004 | WO2004013282A2 Bis (amino acid) molecular scaffolds |
| 02/12/2004 | WO2004013182A1 Hyaluronic acid derivatives |
| 02/12/2004 | WO2004013174A1 Use of disease-associated gene |
| 02/12/2004 | WO2004013153A2 Macrolide compounds endowed with antiinflammatory activity |
| 02/12/2004 | WO2004013147A1 Racemization and enantiomer separation of clopidogrel |
| 02/12/2004 | WO2004013146A1 Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| 02/12/2004 | WO2004013145A1 Pyrrolotriazine kinase inhibitors |
| 02/12/2004 | WO2004013144A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/12/2004 | WO2004013142A1 A riboflavin derivative and its manufacture and uses |
| 02/12/2004 | WO2004013141A1 Condensed pyridines and pyrimidines with tie2 (tek) activity |
| 02/12/2004 | WO2004013140A1 Pyrazole compositions useful as inhibitors of gsk-3 |
| 02/12/2004 | WO2004013138A2 Imidazo`1,2-a!pyridines |
| 02/12/2004 | WO2004013137A1 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity |
| 02/12/2004 | WO2004013136A1 Benzothiophene urea, benzofurane urea, and indole urea, and use of the same as alpha-7 achr agonists |
| 02/12/2004 | WO2004013135A1 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| 02/12/2004 | WO2004013134A2 Compounds |
| 02/12/2004 | WO2004013132A1 Furanthiazole derivatives as heparanase inhibitors |
| 02/12/2004 | WO2004013130A1 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 02/12/2004 | WO2004013125A1 Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway |
| 02/12/2004 | WO2004013120A1 Novel benzodioxoles |
| 02/12/2004 | WO2004013119A1 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| 02/12/2004 | WO2004013114A1 Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
| 02/12/2004 | WO2004013111A1 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers |
| 02/12/2004 | WO2004013110A1 4,4-disubstituted-3,4-dihydro-2(1h)-quinazoliniones useful as hiv reverse transcriptase inhibitors |
| 02/12/2004 | WO2004013108A1 Method and compounds for promoting healing and reducing inflammation |
| 02/12/2004 | WO2004013105A1 Crystalline polymorphic and amorphous forms of benazepril hydrochloride |
| 02/12/2004 | WO2004013102A1 Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines |
| 02/12/2004 | WO2004013101A2 N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy |
| 02/12/2004 | WO2004013099A1 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
| 02/12/2004 | WO2004013093A2 Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| 02/12/2004 | WO2004013091A2 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases |
| 02/12/2004 | WO2004013087A1 Anthranyl derivatives having an anticholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof |
| 02/12/2004 | WO2004013085A1 3-amino-2-hrydroxyalkanoic acids and their prodrugs |
| 02/12/2004 | WO2004012774A1 Conjugates of porphyrin compounds with chemotherapeutic agents |
| 02/12/2004 | WO2004012769A1 Therapeutic inhibitionof protein kinases in cancer cells |
| 02/12/2004 | WO2004012768A1 Tolerance induction with help of a combination of a lfa-1 inhibitor and a costimulation inhibitor and/or a mtor inhibitor |
| 02/12/2004 | WO2004012762A2 Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| 02/12/2004 | WO2004012754A1 Composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs |
| 02/12/2004 | WO2004012753A1 Pharmaceutical composition containing black cumin oil, flax oil and borago oil |
| 02/12/2004 | WO2004012748A1 Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
| 02/12/2004 | WO2004012747A1 Air spray for water intake adjustment |
| 02/12/2004 | WO2004012746A2 New uses for inhibitors of inosine monophosphate dehydrogenase |
| 02/12/2004 | WO2004012744A1 Use of alkyl phosphocholines in combination with antitumor medicaments |
| 02/12/2004 | WO2004012743A1 Antipsoriatic agent |
| 02/12/2004 | WO2004012742A1 Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| 02/12/2004 | WO2004012741A1 Sustained release formulations comprising lamotrigine |
| 02/12/2004 | WO2004012740A1 MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR |
| 02/12/2004 | WO2004012738A1 Novel salt and polymorphs of desloratadine hemifumarate |
| 02/12/2004 | WO2004012737A1 Use or arylsulfonamido-substituted hydroxamid acid matrix metalloproteinase inhibitors for the treatment or prevention of toxemia |
| 02/12/2004 | WO2004012736A1 Biaryl compounds having anti-infective activity |
| 02/12/2004 | WO2004012734A1 Patch for transdermal administration |
| 02/12/2004 | WO2004012733A2 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy |
| 02/12/2004 | WO2004012732A2 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |